Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial

MLA

Mhairi Copland, et al. “Ponatinib with Fludarabine, Cytarabine, Idarubicin, and Granulocyte Colony-Stimulating Factor Chemotherapy for Patients with Blast-Phase Chronic Myeloid Leukaemia (MATCHPOINT): A Single-Arm, Multicentre, Phase 1/2 Trial.” The Lancet Haematology, vol. 9, Feb. 2022, pp. e121–32. EBSCOhost, https://doi.org/10.1016/s2352-3026(21)00370-7.

APA

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jenny L Byrne, Kate Rothwell, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard E Clark, Matthew L Smith, Rachel Fletcher, Rebecca Bishop, Dragana Milojkovic, & Christina Yap. (2022). Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. The Lancet Haematology, 9, e121–e132. https://doi.org/10.1016/s2352-3026(21)00370-7

Chicago

Mhairi Copland, Daniel Slade, Graham McIlroy, Gillian Horne, Jenny L Byrne, Kate Rothwell, Kristian Brock, et al. 2022. “Ponatinib with Fludarabine, Cytarabine, Idarubicin, and Granulocyte Colony-Stimulating Factor Chemotherapy for Patients with Blast-Phase Chronic Myeloid Leukaemia (MATCHPOINT): A Single-Arm, Multicentre, Phase 1/2 Trial.” The Lancet Haematology 9 (February): e121–32. doi:10.1016/s2352-3026(21)00370-7.